Laboratory-scale evaluation of a candidate vaccine for Atlantic salmon against sea lice shows an efficacy of 56 percent when administered by injection.
In targeting grouper for new and sustainable farming technology, the authors developed an oral vaccine to control nervous necrosis virus (NNV) infection at the larval stage and multivalent injective bacterial and viral vaccines for the grow-out stage.
Oral vaccination can be done with virtually all fish sizes and is a relatively stress-free and inexpensive approach. The authors developed a novel oral vaccine delivery system that was found effective against infectious salmon anemia and salmonid rickettsial septicemia at
A virus that causes pancreas disease was patented, but when a vaccine produced by a patent licensee was found insufficient, another company developed a vaccine based on a different strain of the virus. The courts in Norway determined the work
Streptococcus species account for over half of all bacterial diseases in tilapia. The authors studied the ability of biotype-specific vaccines.
A study demonstrated that VP19 and VP28 white spot syndrome virus envelope proteins expressed by replicon particles provided protection against mortality due to WSSV in shrimp.
Vaccines are a proven, cost-effective method to prevent infectious diseases in animals. Current vaccinations for fish can be categorized as killed fish vaccines or modified live vaccines.
Working on a system for oral delivery of IHNV vaccine via fish feed, researchers' goal is to adapt a proven oral DNA-based vaccine given to salmon in Canada to rainbow trout through encapsulation with a polymer or liposome.